By contrast AF102B is a neuroprotective M1 muscarinic agonist in use to treat Sjogren’s syndrome which has been shown to induce APP(s) secretion resulting from alpha-secretase activation of the non-amyloidogenic pathway of APP expression [51,58]. Here, APP is linked to Sjogren syndrome.